Clinical Trial Update: A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

View source ↗

Summary

Pfizer's Litfulo (deucravacitinib) is listed as recruiting for a study to observe its use in people with severe alopecia areata in routine clinical practice.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Litfulo (deucravacitinib)

Snippet

Sponsor: Pfizer | Conditions: Severe Alopecia Areata | Status: RECRUITING